We report more exciting news about the Immunoscore® diagnostic tool developed by our partners at HalioDx! The immuno-oncology diagnostic company, HalioDx announced last week that it has entered into a Collaboration Agreement with the FFCD, the French Cooperative Group dedicated exclusively to digestive oncology, on the Phase II multi-center POCHI trial (FFCD1703 - NCT04262687) in which [...]
Our partners at HalioDx SAS, an immuno-oncology diagnostic company headquartered in Marseille, France, recently announced that their diagnostic test Immunoscore® has been included in the 2020 European Society of Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up for Localised Colon Cancer. Immunoscore® was considered for its ability to refine the prognosis for [...]
Prof Annette Byrne, RCSI, COLOSSUS Coordinator, NPIC Director In Ireland, a new National Preclinical Imaging Centre (NPIC) which will provide enhanced research data to inform new clinical trials that aim to improve patient outcomes, has been awarded funding of €3.4 million under Science Foundation Ireland's (SFI) Research Infrastructure Programme. COLOSSUS Coordinator, Prof Annette [...]
An independent review entitled “Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer” is published on March 30th, 2020 in Molecular Diagnosis and Therapy (Blair, H.A. Mol Diagn Ther (2020)[1] a specialized journal of Springer Nature group that provides researchers and healthcare professionals with insights into the latest molecular diagnostic and therapeutic techniques and their use [...]
